These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 2862316)

  • 21. [Meningococcal meningitis: preliminary epidemiological results on the introduction of a prophylactic vaccine].
    Galli MG
    G Batteriol Virol Immunol; 1982; 75(7-12):251-4. PubMed ID: 7188258
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A second controlled field trial of a serogroup A meningococcal polysaccharide vaccine in Alexandria.
    Wahdan MH; Sallam SA; Hassan MN; Abdel Gawad A; Rakha AS; Sippel JE; Hablas R; Sanborn WR; Kassem NM; Riad SM; Cvjetanović B
    Bull World Health Organ; 1977; 55(6):645-51. PubMed ID: 413639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decline in meningococcal antibody levels in African children 5 years after vaccination and the lack of an effect of booster immunization.
    Ceesay SJ; Allen SJ; Menon A; Todd JE; Cham K; Carlone GM; Turner SH; Gheesling LL; DeWitt W; Plikaytis BD
    J Infect Dis; 1993 May; 167(5):1212-6. PubMed ID: 8486957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Meningococcal meningitis in sub-Saharan Africa: the case for mass and routine vaccination with available polysaccharide vaccines.
    Robbins JB; Schneerson R; Gotschlich EC; Mohammed I; Nasidi A; Chippaux JP; Bernardino L; Maiga MA
    Bull World Health Organ; 2003; 81(10):745-50; discussion 751-5. PubMed ID: 14758435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Evolution of meningococcal infection among infant population in the autonomous community of Valencia (1996-2000). Effectiveness of A+C meningococcal vaccination].
    Goicoechea Sáez M; Fullana Montoro AM; Momparler Carrasco P; Redondo Gallego MJ; Brines Solanes J; Bueno Cañigral FJ
    Rev Esp Salud Publica; 2003; 77(1):125-42. PubMed ID: 12696392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine.
    Dbaibo G; Van der Wielen M; Reda M; Medlej F; Tabet C; Boutriau D; Sumbul A; Anis S; Miller JM
    Int J Infect Dis; 2012 Aug; 16(8):e608-15. PubMed ID: 22704725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Challenges for development of meningococcal vaccines in infants and children.
    Deasy A; Read RC
    Expert Rev Vaccines; 2011 Mar; 10(3):335-43. PubMed ID: 21434801
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The efficacy of meningococcal polysaccharide vaccine in preventing group A meningococcal disease in The Gambia, West Africa.
    Greenwood BM; Smith AW; Hassan-King M; Bijlmer HA; Shenton FC; Hughes AS; Nunn PP; Jack AD; Gowers PR
    Trans R Soc Trop Med Hyg; 1986; 80(6):1006-7. PubMed ID: 3603632
    [No Abstract]   [Full Text] [Related]  

  • 29. Population-Level Persistence of Immunity 2 Years After the PsA-TT Mass-Vaccination Campaign in Mali.
    Basta NE; Borrow R; Berthe A; Dembélé AT; Onwuchekwa U; Townsend K; Boukary RM; Mabey L; Findlow H; Bai X; Sow SO
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S547-53. PubMed ID: 26553687
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effect of 2 vaccination strategies on developments during the epidemic of meningococcal A meningitis in N'Djamena (Chad) in 1988].
    Spiegel A; Greindl Y; Lippeveld T; Decam C; Granga D; Nahor N; Bordonado JL; Sperber G; Yankalbe M; Baudon D
    Bull World Health Organ; 1993; 71(3-4):311-5. PubMed ID: 8324849
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of group C meningococcal vaccine.
    Commun Dis Rep CDR Wkly; 2000 Sep; 10(35):311, 314. PubMed ID: 10992627
    [No Abstract]   [Full Text] [Related]  

  • 32. Meningococcal disease: the advances and challenges of meningococcal disease prevention.
    Yogev R; Tan T
    Hum Vaccin; 2011 Aug; 7(8):828-37. PubMed ID: 21832882
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of the meningococcal C conjugate vaccine in Spain: an epidemiological and microbiological decision.
    Cano R; Larrauri A; Mateo S; Alcalá B; Salcedo C; Vázquez JA
    Euro Surveill; 2004 Jul; 9(7):11-5. PubMed ID: 15318008
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changing epidemiology of meningococcal invasive disease in the Czech republic caused by new clone Neisseria meningitidis C:2a:P1.2(P1.5), ET-15/37.
    Krizova P; Musilek M
    Cent Eur J Public Health; 1995 Nov; 3(4):189-94. PubMed ID: 8903519
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reactogenicity and immunogenicity of a quadrivalent combined meningococcal polysaccharide vaccine in children.
    Lepow ML; Beeler J; Randolph M; Samuelson JS; Hankins WA
    J Infect Dis; 1986 Dec; 154(6):1033-6. PubMed ID: 3097160
    [No Abstract]   [Full Text] [Related]  

  • 36. Long-term persistence of protective antibodies in Dutch adolescents following a meningococcal serogroup C tetanus booster vaccination.
    van Ravenhorst MB; Marinovic AB; van der Klis FR; van Rooijen DM; van Maurik M; Stoof SP; Sanders EA; Berbers GA
    Vaccine; 2016 Dec; 34(50):6309-6315. PubMed ID: 27817957
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Meningococcal C conjugate vaccine effectiveness before and during an outbreak of invasive meningococcal disease due to Neisseria meningitidis serogroup C/cc11, Tuscany, Italy.
    Pezzotti P; Miglietta A; Neri A; Fazio C; Vacca P; Voller F; Rezza G; Stefanelli P
    Vaccine; 2018 Jul; 36(29):4222-4227. PubMed ID: 29895504
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody responses to meningococcal (groups A, C, Y and W135) polysaccharide diphtheria toxoid conjugate vaccine in children who previously received meningococcal C conjugate vaccine.
    El Bashir H; Heath PT; Papa T; Ruggeberg JU; Johnson N; Sinha R; Balfour G; Booy R
    Vaccine; 2006 Mar; 24(14):2544-9. PubMed ID: 16417952
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Control of group C meningococcal disease in Australian aboriginal children by mass rifampicin chemoprophylaxis and vaccination.
    Pearce MC; Sheridan JW; Jones DM; Lawrence GW; Murphy DM; Masutti B; McCosker C; Douglas V; George D; O'Keefe A
    Lancet; 1995 Jul; 346(8966):20-3. PubMed ID: 7603139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2-10 years: a phase II/III double-blind randomized controlled trial.
    Hirve S; Bavdekar A; Pandit A; Juvekar S; Patil M; Preziosi MP; Tang Y; Marchetti E; Martellet L; Findlow H; Elie C; Parulekar V; Plikaytis B; Borrow R; Carlone G; Kulkarni PS; Goel A; Suresh K; Beri S; Kapre S; Jadhav S; Preaud JM; Viviani S; LaForce FM
    Vaccine; 2012 Oct; 30(45):6456-60. PubMed ID: 22898557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.